FLT3 and acute myeloid leukemia: The median age of patients in the overall cohort (n = 571) was 65 years (range, 18–98 years) (Supplementary Figure S1); 331 (58%) were male; ECOG was >2 in 58 (10%); 350 (61%) were de novo AML and 221 (39%) were secondary or therapy-related AML; 77 (14.7%) had the FLT3-ITD mutation; and 38 (7.2%) received front-line FLT3 inhibitors.